GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

1

Multiple myeloma (MM) is a complex malignancy with a 5-year survival rate of 60% and significant morbidity affecting multiple organ systems.
2

GPRC5D is identified as a novel therapeutic target for MM, with potential for T-cell–redirecting agents in clinical development.
3

GPRC5D is predominantly expressed in malignant plasma cells, making it an ideal target for immune therapies with minimal expression in normal tissues.
4

Increased GPRC5D expression in bone marrow correlates with high-risk disease and poor prognosis, though causative relationships remain unproven.
5

GPRC5D expression patterns are independent of BCMA, suggesting potential for combined therapies to address MM heterogeneity.

Blood Cancer Journal

by Paula Rodriguez-Otero, Niels W. C. J. van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar Bahlis, Ajai Chari
February 2, 2024

1